A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Non-obstructive Hypertrophic Cardiomyopathy Trial
Public ClinicalTrials.gov record NCT04826185. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Non-obstructive Hypertrophic Cardiomyopathy
Study identification
- NCT ID
- NCT04826185
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Imbria Pharmaceuticals, Inc.
- Industry
- Enrollment
- 67 participants
Conditions and interventions
Conditions
Interventions
- IMB-1018972 Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 13, 2021
- Primary completion
- Sep 17, 2023
- Completion
- Sep 17, 2023
- Last update posted
- Apr 22, 2024
2021 – 2023
United States locations
- U.S. sites
- 13
- U.S. states
- 10
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Imbria Investigational Site | La Jolla | California | 92093 | — |
| Imbria Investigational Site | Los Angeles | California | 90048 | — |
| Imbria Investigational Site | San Francisco | California | 94143 | — |
| Imbria Investigational Site | Chicago | Illinois | 60611 | — |
| Imbria Investigational Site | Boston | Massachusetts | 02111 | — |
| Imbria Investigational Site | Burlington | Massachusetts | 01805 | — |
| Imbria Investigational Site | St Louis | Missouri | 63110 | — |
| Imbria Investigational Site | Morristown | New Jersey | 07960 | — |
| Imbria Investigational Site | New York | New York | 10016 | — |
| Imbria Investigational Site | Charlotte | North Carolina | 28203 | — |
| Imbria Investigational Site | Portland | Oregon | 97239 | — |
| Imbria Investigational Site | Houston | Texas | 77030 | — |
| Imbria Investigational Site | Salt Lake City | Utah | 84112 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04826185, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 22, 2024 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04826185 live on ClinicalTrials.gov.